NV40 Stock Chart & Stats
€0.29
€0.00(0.00%)
At close: 4:00 PM EDT
€0.29
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€18.53M
Enterprise Value€1.54
Total Cash (Recent Filing)€33.99M
Total Debt (Recent Filing)€1.53M
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Oct 29, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding9,452,108
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.26Price Target Upside3436.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityThe reported response rates and duration of response provide meaningful clinical validation for iopofosine in heavily treated patients. If these outcomes are confirmed in later-stage testing, they could support differentiation, regulatory progress, and eventual adoption in an area with substantial unmet need.
Defined Regulatory PathwayA planned confirmatory Phase III study and a Breakthrough Designation create a defined route toward potential approval rather than leaving the lead program at an exploratory stage. Regulatory progress over the next several quarters could materially reduce development uncertainty and clarify the company’s commercial trajectory.
Low Leverage And Improved Capital BaseMinimal debt reduces fixed financial obligations while the rebuilt equity base provides a stronger foundation for clinical execution than the prior negative-equity position. This structure preserves flexibility to direct capital toward development and limits balance-sheet pressure while the pipeline remains pre-commercial.
Bears Say
Pre-commercial Business ModelWith no reported revenue, the company has not yet demonstrated a commercial income stream or operating leverage from its therapies. Its financial outlook therefore remains dependent on successful clinical development and future approval, making setbacks more consequential than for an established drug business.
Persistent Cash BurnOngoing negative operating and free cash flow means clinical programs must continue to be funded externally until product revenue or other durable inflows emerge. Even with improvement from 2024, continued burn can consume capital, constrain program choices, and increase dependence on future financing.
Clinical Execution And Funding UncertaintyThe lead program still depends on coordinating sites, approvals, radiopharmacy readiness, and other operational steps before enrollment can proceed at scale. In addition, much of the announced financing is milestone contingent, so execution delays could affect both regulatory timing and available development capital.
Cellectar Biosciences News
NV40 FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was €0.28 and its highest was €0.29 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is €18.53M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Oct 29, 2026 which is in 33 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Aug 13, 2026. The company reported -€0.492 earnings per share for the quarter, missing the consensus estimate of -€0.449 by -€0.043.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.48.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 9,452,108 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -€0.492 in its last earnings report, missing expectations of -€0.449. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in DE:NV40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
NV40 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical validation for iopofosine (durable responses and high response rates including a near-80% major response in the BTKi-exposed subgroup), clear progress toward a confirmatory Phase III and an intended accelerated approval filing in 1H 2027, plus meaningful balance-sheet reinforcement from an oversubscribed financing. The company is also advancing CLR 125 and expanding its PDC platform with supporting peer-reviewed data and manufacturing readiness. Offsetting these positives are materially higher R&D costs, a wider net loss in dollar terms, timing and operational risks tied to site activation/IRB/radiopharmacy readiness, just-in-time isotope production complexities, actinium-225 supply risk for alpha programs, and potential dilution from issued warrants. Overall, the highlights (clinical data, regulatory path, financing, pipeline expansion and manufacturing preparedness) materially outweigh the operational and financing caveats.View all DE:NV40 earnings summariesNV40 Stock 12 Month Forecast
Average Price Target
€10.26
▲(3436.60% Upside)